Cofoe Medical Technology Co.,Ltd. (SHE:301087)
China flag China · Delayed Price · Currency is CNY
47.03
-2.60 (-5.24%)
At close: Nov 13, 2026

Cofoe Medical Technology Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
4,0453,2522,8422,7062,8692,129
Other Revenue
135.86135.86141.38148.02108.05146.74
4,1813,3872,9832,8542,9772,276
Revenue Growth
33.48%13.56%4.53%-4.14%30.82%-4.19%
Cost of Revenue
1,8971,6191,4681,6701,8391,296
Gross Profit
2,2841,7681,5151,1841,137979.57
Selling, General & Admin
1,7281,3311,095851.63740.79471.08
Research & Development
106.1187.2896.41114.33118.4270.59
Other Operating Expenses
40.6215.69.258.1812.656.24
Operating Expenses
1,8741,4341,206973.55886.23558.69
Operating Income
409.76334.51309.35210.31251.23420.89
Interest Expense
-5.05-16.07-17.91-13.5-10.85-6.81
Interest & Investment Income
5.8142.2754.7182.02102.6414.41
Currency Exchange Gain (Loss)
-4.14-4.140.520.160.36-0.19
Other Non Operating Income (Expenses)
-13.28-4.67-1.9-3.27-2.49-0.44
EBT Excluding Unusual Items
393.09351.91344.78275.71340.89427.86
Impairment of Goodwill
-----0.15-
Gain (Loss) on Sale of Investments
49.8249.849.4-1.564.46.02
Gain (Loss) on Sale of Assets
-0.07-1.375.884.596.470.14
Asset Writedown
8.370.18-2.32-2.24-35.14-0.05
Legal Settlements
1.451.452.19-2.41--0.16
Other Unusual Items
34.3923.8312.0711.6117.9174.51
Pretax Income
487.05425.84372285.71334.39508.33
Income Tax Expense
69.6655.5359.6632.8432.3778.74
Earnings From Continuing Operations
417.4370.32312.34252.87302.02429.59
Minority Interest in Earnings
-0.761.29-0.591.41-0.34-0.73
Net Income
416.64371.61311.75254.28301.68428.86
Net Income to Common
416.64371.61311.75254.28301.68428.86
Net Income Growth
30.18%19.20%22.60%-15.71%-29.65%1.16%
Shares Outstanding (Basic)
215204204205208165
Shares Outstanding (Diluted)
218205206205208165
Shares Change
5.71%-0.20%0.46%-1.70%26.56%5.47%
EPS (Basic)
1.941.831.531.241.452.60
EPS (Diluted)
1.921.811.511.241.452.60
EPS Growth
23.58%19.87%21.77%-14.48%-44.23%-4.25%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
228.92517.63542.920.6-540.87-273.25
Free Cash Flow Per Share
1.052.522.640.10-2.60-1.66
Dividend Per Share
1.2001.8001.8001.2001.2001.231
Dividend Growth
-33.33%0%50.00%0%-2.50%-
Gross Margin
54.62%52.20%50.79%41.48%38.21%43.05%
Operating Margin
9.80%9.88%10.37%7.37%8.44%18.50%
Profit Margin
9.97%10.97%10.45%8.91%10.13%18.85%
Free Cash Flow Margin
5.48%15.28%18.20%0.72%-18.17%-12.01%
EBITDA
532.97448.85411.86293.98292.34449.78
EBITDA Margin
12.75%13.25%13.81%10.30%9.82%19.77%
D&A For EBITDA
123.21114.33102.5183.6741.1128.89
EBIT
409.76334.51309.35210.31251.23420.89
EBIT Margin
9.80%9.88%10.37%7.37%8.44%18.50%
Effective Tax Rate
14.30%13.04%16.04%11.49%9.68%15.49%
Revenue as Reported
989.713,3872,9832,8542,9772,276
Advertising Expenses
-328.12225.57206.59151.9686.71